Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Fig. 6

Therapeutic efficacy of H5B14-based ADCs in multiple tumor xenograft models: a and b Inhibitory effect of H5B14-MMAE and H5B14-DCM on xenograft tumor growth. Tumors mediated by H358, HT-29, L3.6pl, and T-47D cell lines were used as the model. LoVo cell-derived tumors without RON expression served as the control. Athymic nude mice (5 mice per group) were subcutaneously inoculated with 5 × 106 cells. H5B14-MMAE (a) or H5B14-DCM (b) at 20 mg/kg in a single injection was administered through tail vein after tumors volumes reached ~ 150 mm3. Mice injected with CmIgG-MMAE at 20 mg/kg were used as the control. To establish the effect-time relationship, the estimated reduction of H-Zt/g4-MMAE in vivo according to the t½ was marked as red circles [6]. c and d Effect of H5B14-based ADCS on tumor weight and number. Individual tumors from different groups described in (a) and (b) were collected at the end of study. All tumors were weighed to reach the average tumor weight per group, which was used to obtain the percentages of tumor growth inhibition. The number of tumors was counted to determine the eradication effect of H5B14-based ADCs. NF, no tumors were found in the injected site

Back to article page